205 related articles for article (PubMed ID: 25723113)
1. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations and PTEN loss in salivary duct carcinomas.
Griffith CC; Seethala RR; Luvison A; Miller M; Chiosea SI
Am J Surg Pathol; 2013 Aug; 37(8):1201-7. PubMed ID: 23851329
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
4. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Chiosea SI; Thompson LD; Weinreb I; Bauman JE; Mahaffey AM; Miller C; Ferris RL; Gooding WE
Cancer; 2016 Oct; 122(20):3136-3144. PubMed ID: 27379604
[TBL] [Abstract][Full Text] [Related]
5. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type.
Hsieh MS; Lee YH; Jin YT; Kuo YJ
Virchows Arch; 2020 Oct; 477(4):581-592. PubMed ID: 32383006
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
8. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.
Ku BM; Jung HA; Sun JM; Ko YH; Jeong HS; Son YI; Baek CH; Park K; Ahn MJ
J Transl Med; 2014 Oct; 12():299. PubMed ID: 25343854
[TBL] [Abstract][Full Text] [Related]
9. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
[TBL] [Abstract][Full Text] [Related]
10. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.
Bahrami A; Perez-Ordonez B; Dalton JD; Weinreb I
Histopathology; 2013 Aug; 63(2):250-62. PubMed ID: 23738717
[TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
13. Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland.
Weinreb I; Bishop JA; Chiosea SI; Seethala RR; Perez-Ordonez B; Zhang L; Sung YS; Chen CL; Assaad A; Oliai BR; Antonescu CR
Am J Surg Pathol; 2018 Apr; 42(4):442-452. PubMed ID: 29443014
[TBL] [Abstract][Full Text] [Related]
14. Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?
Rooper LM; Gagan J; Bishop JA
Head Neck Pathol; 2022 Dec; 16(4):1063-1072. PubMed ID: 35794510
[TBL] [Abstract][Full Text] [Related]
15. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
16. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
Dogan S; Ng CKY; Xu B; Kumar R; Wang L; Edelweiss M; Scott SN; Zehir A; Drilon A; Morris LGT; Lee NY; Antonescu CR; Ho AL; Katabi N; Berger MF; Reis-Filho JS
Hum Pathol; 2019 Jun; 88():66-77. PubMed ID: 30946933
[TBL] [Abstract][Full Text] [Related]
17. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
18. Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.
Bishop JA; Gagan J; Krane JF; Jo VY
Head Neck Pathol; 2020 Dec; 14(4):869-875. PubMed ID: 31989433
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
20. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
